Unknown

Dataset Information

0

The impact of viral evolution and frequency of variant epitopes on primary and memory human immunodeficiency virus type 1-specific CD8? T cell responses.


ABSTRACT: It is unclear if HIV-1 variants lose the ability to prime naïve CD8(+) cytotoxic T lymphocytes (CTL) during progressive, untreated infection. We conducted a comprehensive longitudinal analysis of viral evolution and its impact on primary and memory CD8(+) T cell responses pre-seroconversion (SC), post-SC, and during combination antiretroviral therapy (cART). Memory T cell responses targeting autologous virus variants reached a nadir by 8 years post-SC with development of AIDS, followed by a transient enhancement of anti-HIV-1 CTL responses upon initiation of cART. We show broad and high magnitude primary T cell responses to late variants in pre-SC T cells, comparable to primary anti-HIV-1 responses induced in T cells from uninfected persons. Despite evolutionary changes, CD8(+) T cells could still be primed to HIV-1 variants. Hence, vaccination against late, mutated epitopes could be successful in enhancing primary reactivity of T cells for control of the residual reservoir of HIV-1 during cART.

SUBMITTER: Melhem NM 

PROVIDER: S-EPMC4110927 | biostudies-literature | 2014 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

The impact of viral evolution and frequency of variant epitopes on primary and memory human immunodeficiency virus type 1-specific CD8⁺ T cell responses.

Melhem Nada M NM   Smith Kellie N KN   Huang Xiao-Li XL   Colleton Bonnie A BA   Jiang Weimin W   Mailliard Robbie B RB   Mullins James I JI   Rinaldo Charles R CR  

Virology 20131220


It is unclear if HIV-1 variants lose the ability to prime naïve CD8(+) cytotoxic T lymphocytes (CTL) during progressive, untreated infection. We conducted a comprehensive longitudinal analysis of viral evolution and its impact on primary and memory CD8(+) T cell responses pre-seroconversion (SC), post-SC, and during combination antiretroviral therapy (cART). Memory T cell responses targeting autologous virus variants reached a nadir by 8 years post-SC with development of AIDS, followed by a tran  ...[more]

Similar Datasets

| S-EPMC2836785 | biostudies-literature
| S-EPMC1526708 | biostudies-literature
| S-EPMC1637592 | biostudies-literature
| S-EPMC8456706 | biostudies-literature
| S-EPMC7806261 | biostudies-literature
| S-EPMC10571600 | biostudies-literature
| S-EPMC10957963 | biostudies-literature
| S-EPMC2840337 | biostudies-other
| S-EPMC7239382 | biostudies-literature
| S-EPMC2708622 | biostudies-literature